SRRK stock forecast, quote, news & analysis
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases... Show more
Why Scholar Rock Holding Corporation (SRRK) Is Up +12% in the Last 30 Days
Key Takeaways
- SRRK stock rose +12% over the past 30 days, driven primarily by the company's resubmission of its Biologics License Application (BLA) for apitegromab to the FDA on March 31.
- Over the past quarter, shares gained +8%, reflecting sustained investor optimism around the apitegromab program for spinal muscular atrophy (SMA) amid positive analyst updates.
- High trading volumes in late March coincided with the BLA news, indicating strong market sentiment shifts.
- Key factors include FDA interactions, manufacturing resolutions, and sector interest in SMA therapies.
- Fundamentals highlight cash reserves of $368 million, supporting near-term catalysts despite ongoing losses.
Scholar Rock Holding Corporation (SRRK) Company Overview and Market Position
Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing innovative therapies that modulate protein growth factors to treat serious diseases. Its lead candidate, apitegromab, targets SMA, a rare neuromuscular disorder, as an adjunct to standard-of-care treatments like nusinersen or gene therapy. The company's business model centers on advancing selective inhibitors through clinical stages toward commercialization, with a pipeline also exploring other neuromuscular and cardiometabolic conditions.
In the competitive biotech landscape, Scholar Rock differentiates through its proprietary platform for highly selective antibodies. Recent stock price movement aligns with progress in its SMA program, where positive Phase 3 data has positioned apitegromab as a potential first-in-class muscle-targeted therapy, boosting investor confidence in its market potential amid a growing rare disease sector.
Scholar Rock Holding Corporation (SRRK) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SRRK stock advanced from a March 20 closing price of $44.64 to $50.00 as of April 16, marking a +12% gain. The movement was volatile and trend-driven, with sharp gains in late March fueled by high volumes exceeding 3 million shares on multiple days.
For the past quarter, shares climbed +8% from $46.53 on January 15 to the current $50.00 level. Performance was relatively steady with upward momentum building toward quarter-end, punctuated by volume spikes and less pronounced daily swings compared to the recent 30-day period.
What Drove SRRK Stock Price in the Last 30 Days
The primary catalyst was Scholar Rock's March 31 resubmission of the BLA for apitegromab to the FDA, following a Complete Response Letter (CRL) in September 2025 related to manufacturing observations at a third-party site. The company addressed these by adding a second fill-finish facility and confirming FDA reinspection clearance, sparking a multi-day rally. Shares jumped from around $40 on March 18 to over $45 by March 19, with further gains to $49 by March 31 amid elevated volumes of over 5 million shares that day.
Analyst enthusiasm amplified the move, with firms like Wedbush raising price targets to $58 and maintaining outperform ratings, citing strong Phase 3 efficacy in motor function improvements for SMA patients. Biotech sector sentiment and short interest covering also contributed to the upward pressure.
What Drove SRRK Stock Performance Over the Last Quarter
The quarterly uptrend stemmed from building anticipation for the BLA resubmission, highlighted by January strategic updates outlining 2026 priorities including U.S. launch readiness post-approval. Q4 2025 earnings in early March, despite a net loss of $91 million, reaffirmed cash runway into 2027 and pipeline progress, stabilizing shares around $44-46 before the late-March surge.
Broader neuromuscular therapy demand, positive Phase 3 SAPPHIRE study results from prior periods, and institutional accumulation supported cumulative gains. Macro factors like favorable biotech funding environment and interest rate stability aided risk-on sentiment in small-cap biotechs, with SRRK outperforming peers on SMA-specific catalysts.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds that analyze and trade thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum plays, across short-term day trades to longer swing positions. Performance metrics like win rate, average return, and Sharpe ratio help users identify relevant tools for their style, with real-time updates reflecting live trading results. Whether scanning for biotech breakouts like SRRK or broad market trends, these bots provide data-backed signals. Explore the page to discover bots matching your risk tolerance and timeframe today.
SRRK Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor FDA acceptance of the apitegromab BLA, expected within 30 days, and the PDUFA (Prescription Drug User Fee Act) target action date in late September 2026. Upcoming Q1 2026 earnings on May 7 will detail financials and manufacturing updates. Ongoing EMA (European Medicines Agency) interactions for ex-U.S. approval, pipeline advancements in other indications, and cash burn amid no revenue remain key. Sector trends in SMA adjunct therapies, competitor developments, and biotech M&A (mergers and acquisitions) activity could sway sentiment. Regulatory risks, clinical data readouts, and macroeconomic shifts in healthcare funding warrant close attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for SRRK turns positive, indicating new upward trend
SRRK saw its Momentum Indicator move above the 0 level on June 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SRRK just turned positive on June 17, 2026. Looking at past instances where SRRK's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
SRRK moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for SRRK crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRRK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SRRK broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.368) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). SRRK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a r&d company in biotechnology
Industry Biotechnology